CLL Market Snapshot: Seismic Changes Rock The Treatment Landscape

The market for chronic lymphocytic leukemia drugs is undergoing big changes, with three new drugs approved: Roche’s antibody Gazyva and two oral therapies from Pharmacyclics/J&J and Gilead. Side effect profiles, administration and progression-free survival rates are helping to guide treatment decisions.